Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTPN11 | Q06124 | 1/20 | 0.37 |
| ▸ | MKNK1 | Q9BUB5 | 1/20 | 0.36 |
| ▸ | MKNK2 | Q9HBH9 | 1/20 | 0.36 |
| ▸ | HSD11B1 | P28845 | 4/20 | 0.36 |
| ▸ | PIM1 | P11309 | 1/20 | 0.34 |
| ▸ | CCNT1 | O60563 | 1/20 | 0.32 |
| ▸ | CDK4 | P11802 | 1/20 | 0.32 |
| ▸ | CCND1 | P24385 | 1/20 | 0.32 |
| ▸ | CCND3 | P30281 | 1/20 | 0.32 |
| ▸ | CDK7 | P50613 | 1/20 | 0.32 |
| ▸ | CDK9 | P50750 | 1/20 | 0.32 |
| ▸ | CCNH | P51946 | 1/20 | 0.32 |
| ▸ | MNAT1 | P51948 | 1/20 | 0.32 |
| ▸ | CDK6 | Q00534 | 1/20 | 0.32 |
| ▸ | CDK5 | Q00535 | 1/20 | 0.32 |
| ▸ | CDK5R1 | Q15078 | 1/20 | 0.32 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.31 |
| ▸ | OPRL1 | P41146 | 1/20 | 0.31 |
| ▸ | AVPR1A | P37288 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1160741 | 0.79 | HSD11B1 (0.46) | PTPN11MKNK1MKNK2HSD11B1PIM1 | |
| SCHEMBL1159359 | 0.79 | MKNK1 (0.39) | PTPN11MKNK1MKNK2HSD11B1PIM1 | |
| SCHEMBL8509658 | 0.78 | HSD11B1 (0.60) | HSD11B1 | |
| SCHEMBL974634 | 0.77 | KDM4E (0.47) | PTPN11MKNK1MKNK2HSD11B1 | |
| SCHEMBL972838 | 0.77 | PTPN11 (0.39) | PTPN11MKNK1MKNK2HSD11B1PIM1 | |
| SCHEMBL8509465 | 0.76 | PTPN11 (0.42) | PTPN11MKNK1MKNK2HSD11B1PIM1 | |
| SCHEMBL8511584 | 0.76 | HSD11B1 (0.41) | PTPN11MKNK1MKNK2HSD11B1PIM1 | |
| SCHEMBL8509241 | 0.75 | PTPN11 (0.41) | PTPN11MKNK1MKNK2HSD11B1PIM1 | |
| SCHEMBL974017 | 0.74 | SMO (0.38) | PTPN11MKNK1MKNK2HSD11B1CCNT1 | |
| SCHEMBL974412 | 0.74 | HSD11B1 (0.51) | MKNK1MKNK2HSD11B1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2459549-B1 | TETRAHYDROQUINOXALINE UREA DERIVATIVES, PREPARATION THEREOF, AND THERAPEUTIC USE THEREOF | SANOFI SA (FR) | 2014-11-19 | — | — | EP | disclosed |
| US-8530473-B2 | Tetrahydroquinoxaline urea derivatives as modulators of 11β-hydroxysteroid dehydrogenase type 1 | SANOFI (FR) | 2013-09-10 | — | — | US | disclosed |
| EP-2459549-A1 | TETRAHYDROQUINOXALINE UREA DERIVATIVES, PREPARATION THEREOF, AND THERAPEUTIC USE THEREOF | SANOFI (FR) | 2012-06-06 | — | — | EP | disclosed |
| US-20120135958-A1 | TETRAHYDROQUINOXALINE UREA DERIVATIVES, PREPARATION THEREOF, AND THERAPEUTIC USE THEREOF | SANOFI (FR) | 2012-05-31 | — | — | US | disclosed |
| WO-2011012801-A1 | TETRAHYDROQUINOXALINE UREA DERIVATIVES, PREPARATION THEREOF, AND THERAPEUTIC USE THEREOF | SANOFI-AVENTIS (FR) | 2011-02-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120135958-A1 | TETRAHYDROQUINOXALINE UREA DERIVATIVES, PREPARATION THEREOF, AND THERAPEUTIC USE THEREOF | CBR3, CBR1, OXGR1 | PTPN11 2077/4885MKNK1 3938/4885MKNK2 3052/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.